Clinical Study of ASN-3186 in Patients with Advanced Solid Tumors

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

200

Participants

Timeline

Start Date

February 20, 2025

Primary Completion Date

March 20, 2029

Study Completion Date

September 20, 2029

Conditions

Advanced Solid Tumors

Interventions

DRUG

ASN-3186

ASN-3186 will be administered orally.

DRUG

ASN-3186

ASN-3186 will be administered orally.

DRUG

ASN-3186

ASN-3186 will be administered orally.

All Listed Sponsors

lead

Jiangsu Yahong Meditech Co., Ltd aka Asieris

INDUSTRY

NCT06787950 - Clinical Study of ASN-3186 in Patients with Advanced Solid Tumors | Biotech Hunter | Biotech Hunter